Monday, May 02, 2016 2:02:09 PM
Conference Call and Webcast to Follow
VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 29, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call and webcast on Wednesday, May 4, 2016 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to provide a corporate update and first quarter financial results.
Conference Call and Webcast Information
Arbutus will hold a conference call and webcast on Wednesday, May 4, 2016, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to provide a corporate update and report its first quarter 2016 financial results. A live webcast of the call can be accessed through the Investor section of Arbutus’ website at www.arbutusbio.com. Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 2861586.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.
Contact Information
Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604.419.3200
Email: acutler@arbutusbio.com
Helia Baradarani
Manager, Investor Relations
Phone: 604.419.3200
Email: hbaradarani@arbutusbio.com
Media
Please direct all media inquiries to: media@arbutusbio.com
https://www.sec.gov/Archives/edgar/data/1447028/000117184316009506/exh_991.htm
To follow KarinCA, click here then click "Follow This Member" under my photo.
Be kinder than necessary, for everyone you meet is fighting some kind of battle.
Recent ABUS News
- Arbutus to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/08/2024 08:17:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:13:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 11:31:17 AM
- Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 07/18/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 03:16:15 PM
- Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels • GlobeNewswire Inc. • 06/06/2024 03:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 10:00:21 AM
- Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure • GlobeNewswire Inc. • 06/05/2024 06:30:00 AM
- Arbutus to Participate in Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 08:25:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:10:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:07:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 10:00:18 AM
- Arbutus to Present Imdusiran Data at EASL Congress 2024 • GlobeNewswire Inc. • 05/22/2024 06:00:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 01:03:23 PM
- Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value • Business Wire • 05/17/2024 01:00:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/09/2024 12:00:20 PM
- Arbutus to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 11:30:00 AM
- Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 • GlobeNewswire Inc. • 05/02/2024 11:25:00 AM
- Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 04/18/2024 11:30:00 AM
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna • GlobeNewswire Inc. • 04/04/2024 12:30:49 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM